---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-023742"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:54:39.903554+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth

## Summary
- Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
- GAAP net loss $34M ($0.60 loss per share); adjusted EPS $0.44 vs $0.48.
- Orders outpaced sales by 6% in Q4; sequential revenue up 8%.
- FY2025 guidance: revenue $685-710M (8-12% reported growth, 10-14% ex-COVID).
- Closed acquisition of Tantti Laboratory; launched AVIPure dsRNA resin for mRNA.

## SEC filing metadata
- accession: 0000950170-25-023742
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/0000950170-25-023742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/rgen-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-023742
- JSON: https://secwatch.observer/filing/0000950170-25-023742.json
- Plain text: https://secwatch.observer/filing/0000950170-25-023742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.